Introduction
============

Saliva is a plasma ultra-filtrate that includes specific salivary proteins produced by three major salivary glands (parotid, sub-mandibular and sub-lingual) and other smaller glands ([@b1-bmi-03-25]). Salivary glands produce around 750 ml of fluid each day ([@b3-bmi-03-25]). After secretion in the mouth cavity, the fluid is mixed with bacteria, lining cells, nasal secretions and bronchial secretions and is termed whole saliva ([@b13-bmi-03-25]; [@b14-bmi-03-25]). Whole saliva is easy to collect in a non-invasive way. This makes saliva an attractive alternative to blood testing ([@b14-bmi-03-25]; [@b15-bmi-03-25]). Compared to blood sampling, whole saliva collection requires no specially trained personnel, can reduce discomfort and anxiety and may simplify serial sample collection. Saliva tests are also safer than blood tests regarding the risk for hepatitis and HIV. As a diagnostic fluid, saliva has been studied in pilot experiments for several pathological conditions, such as celiac disease ([@b16-bmi-03-25]), rheumatoid arthritis ([@b8-bmi-03-25]), HIV ([@b9-bmi-03-25]; [@b18-bmi-03-25]; [@b19-bmi-03-25]; [@b5-bmi-03-25]), diabetes mellitus ([@b2-bmi-03-25]; [@b17-bmi-03-25]), preterm birth ([@b7-bmi-03-25]; [@b24-bmi-03-25]), breast cancer ([@b27-bmi-03-25]; [@b28-bmi-03-25]), sjögren's syndrome ([@b25-bmi-03-25]) and for evaluation of hematopoietic stem cell transplantation ([@b12-bmi-03-25]). Saliva composition is influenced by several factors, e.g. circadian rhythms, oral health status and exercise ([@b4-bmi-03-25]; [@b3-bmi-03-25]) but also micro organisms and proteases may have a considerable effect on sample stability/protein degradation. Before saliva can be used as a diagnostic fluid for protein markers in the clinic, its stability should be determined. At present there are only three studies on protein stability in saliva samples ([@b21-bmi-03-25]; [@b23-bmi-03-25]; [@b26-bmi-03-25]). Two of the studies report on the stability of specific proteins i.e. IgA, Lysozyme ([@b23-bmi-03-25]) and IgG ([@b21-bmi-03-25]). One recent study determined overall protein stability of saliva samples stored on ice, at −20 °C and at −80 °C ([@b26-bmi-03-25]). In the current study we evaluated in detail the overall protein stability of saliva at room temperature over the first four hours after sample collection since this is a critical period where protein breakdown could be expected. The effect of sample handling, inhibition of bacterial growth and inhibition of protease activity on saliva protein stability was examined by comparative profiling with Surface Enhanced Laser Desorption/Ionization Time of Flight Mass Spectrometry (SELDI-TOF-MS) ([@b20-bmi-03-25]). In addition we studied whole saliva composition. Whole saliva protein composition has been studied using different proteomic strategies ([@b11-bmi-03-25]; [@b29-bmi-03-25]; [@b31-bmi-03-25]; [@b10-bmi-03-25]; [@b32-bmi-03-25]; [@b6-bmi-03-25]; [@b30-bmi-03-25]). Xie et al. ([@b32-bmi-03-25]) identified 437 proteins in saliva using free flow electrophoreses. Guo et al. ([@b6-bmi-03-25]) could identify 1381 proteins employing a capillary electrophoresis approach. However, because of the complexity of whole saliva, each proteomics strategy leads to partial overlapping subsets of saliva proteins ([@b6-bmi-03-25]). Therefore, different proteomics strategies contribute to a comprehensive view of the whole saliva proteome. We analyzed whole saliva composition by fractionating saliva proteins on SDS-PAGE followed by LC-MS/MS analyses of digests from cut-out sections of the gel lane. This proteomics approach has not been applied to saliva before. The results of this approach are compared to previous proteomics studies on whole saliva and discussed in terms of protein origin and function.

Materials and Methods
=====================

Chemicals
---------

Ammonium bicarbonate, triton X-100, azide, phenylmethylsulphonylfluoride (PMSF), EDTA, ditiothreitol (DTT), iodoacetamide, α-cyano-4-hydroxy cinnamic acid diethylamine salt (CHCA), formic acid (FA) and trifluoroacetic acid (TFA) were purchased from Sigma-Aldrich (Steinheim, Germany). Acetonitrile (ACN) and acetone were obtained from Biosolve (Valkenswaard, The Netherlands), leupeptin from Roche (Mannheim, Germany) and ammonium acetate and 2-propanol from Merck (Darmstadt, Germany). MES running buffer and SeeBlue Pre-Stained standard for SDS-PAGE were obtained from Invitrogen (Breda, The Netherlands). Coomassie staining (PageBlue Staining Solution) was from Fermentas (Vilnius, Lithuania). Seq. grade modified trypsin porcine was purchased from Promega (Madison, WI, U.S.A.).

Saliva collection
-----------------

Whole saliva was collected from healthy subjects, four male and three female, between 08:00 a.m. and 10:00 a.m. after overnight fasting, to minimize the influence of circadian rhythms and food debris. Subjects were asked to rinse their mouths with water and discard this before sample collection. Saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was then spit into a polypropylene test tube and this was repeated until enough saliva was collected ([@b22-bmi-03-25]). During the collection process the sample tubes were kept on ice.

Sample pretreatment
-------------------

Samples were processed according to Hu et al. ([@b10-bmi-03-25]). Briefly, samples were centrifuged for 5 minutes at 1300 g at 4 °C. The pellet was discarded (debris) and the supernatant was centrifuged for 15 minutes at 14000 g at 4 °C. After centrifugation, the supernatant was stored at −20 °C until analysis. Samples were analyzed the same day.

Sample stability studies
------------------------

In the first experiment, sample stability was determined in saliva obtained from seven healthy volunteers (four male, three female). Freshly collected saliva samples were either directly processed (time point 0) or left at room temperature for four hrs before processing. Aliquots of the 0 and 4 hrs time points were then analyzed by SELDI-TOF-MS in duplicate (see below).

In a second experiment a unique saliva sample freshly collected from one healthy male volunteer was divided in 3 aliquots of 1.2 ml and incubated for 0, 0.5, 1 and 4 hrs at room temperature with either a) 40 μl of 100 mM sodium azide to inhibit bacterial activity, b) protease inhibitors: 60 μl of 2 mg/ml PMSF in 2-propanol, 1.2 μl of 1 mg/ml leupeptin in water, 12 μl of 100 mM EDTA, or c) no additives (control). Water was added to a final volume of 1.273 ml for all 3 conditions. At each time point an aliquot was taken and treated as described above (sample pre-treatment section). Thereafter, samples were analyzed in triplicate by SELDI-TOF-MS for protein profiling.

CM10 weak cation exchange proteinchip arrays (Ciphergen biosystems, Fremont, CA, U.S.A.) were assembled in a 96 well bioprocessor and the spots were washed two times with 200 μl binding buffer (100 mM NH~4~Ac pH 4.0, 0.05% Triton X-100) for 5 minutes with vigorous shaking. After removing the buffer from the wells, 90 μl binding buffer and 10 μl saliva sample were randomly applied to the spots (in duplicate or triplicate as detailed above). Samples were allowed to incubate for 30 minutes with continuous shaking. Then, they were removed and spots were washed 3 times with 200 μl binding buffer for 5 minutes and once with 200 μl de-ionized water for 5 minutes. The chips were removed from the bioprocessor and air-dried for 15 minutes, followed by two additions (1 μl each) of a 20% solution of CHCA prepared in 50% ACN and 0.5% TFA. Spots were analyzed using the ProteinChip Reader (model PBS II, Ciphergen Biosystems). The mass spectrometer was calibrated using the All-in-One peptide calibration kit (Ciphergen Biosystems) with a focus mass of 6000 Da. Spectra from the saliva samples were collected with the proteinchip software 3.1 (Ciphergen Biosystems) in the mass range 1--20 kDa. Laser intensity was 190, ionsource voltage 20000 V and detector voltage 2150 V. Cluster analysis was performed by Ciphergen Express 3.0 software (Ciphergen Biosystems): a) between samples collected at 0 hr and 4 hr, combining spectra of all seven volunteers measured in duplicate (28 spectra in total) and b) between different time points (0 hrs, 0.5 hrs, 1 hr and 4 hrs) for every condition (control, in presence of azide and in presence of protease inhibitors) measured in triplicate. Before cluster analyses, spectra to be compared were selected, the baseline was subtracted and profiles were normalized using total ion current. Peaks with a signal to noise ratio higher than 5 were selected and were clustered with peaks with similar masses (mass deviation 0.3%) in other profiles with signal to noise ratios higher than 2. The percentage of spectra in which a peak must appear in order to form a cluster was set to 20%. Significant differences (p \< 0.05) in peak height of particular masses were calculated.

Saliva protein composition
--------------------------

A saliva sample freshly obtained from a healthy volunteer was processed immediately after collection as described in the sample pretreatment section. 10 μl of processed saliva were mixed with NuPAGE LDS sample buffer (Invitrogen, Carlsbad, CA, U.S.A.) according to standard protocol from the manufacturer. SDS-PAGE was then performed on a NuPAGE 12% Bis-Tris gel (Invitrogen) run at 200 V for 50 minutes with MES buffer (Invitrogen). Proteins were visualized with Coomassie staining. For protein identification, the whole lane was excised in 30 bands. Each band was cut into small pieces and stored at −20 °C until analysis. Then, they were washed in water and dehydrated in ACN. Reduction was performed by covering gel pieces with 10 mM DTT in 100 mM ammonium bicarbonate for 1 hr at 60 °C. DTT solution was then replaced by 55 mM iodoacetamide in 100 mM ammonium bicarbonate and gel pieces were incubated at room temperature in the dark for 45 minutes. After washing in water and dehydration in ACN, 0.1 μg of trypsin (in 50 mM ammonium bicarbonate) was added and gel pieces were allowed to rehydrate on ice for 20 minutes. Digestion was carried out overnight at 37 °C. Peptides were extracted by treating the gel pieces with 0.1%FA for 30 minutes with continuous shaking. Peptide mixtures were then stored at −20 °C until LC-MS/MS analysis was performed.

Separation of the resulting tryptic peptide mixtures was performed by nano-scale reversed-phase LC-MS/MS. The Agilent 1100 nanoflow/capillary LC system (Agilent, Paolo Alto, CA, U.S.A.) was equipped with a trapping column (5 × 0.3 mm C~18~RP) (Dionex/LC Packings, Amsterdam, The Netherlands) and a nanocolumn (150 × 0.075 mm, C~18~Pepmap) (Dionex/LC Packings). Peptides mixtures were injected into the trapping column at a flow rate of 10 μl/min (3%ACN/0.1%TFA). After 10 minutes the trapping column was switched into the nanoflow system and the trapped peptides were separated using the nanocolumn at a flow rate of 0.3 μl/min in a linear gradient elution from 95%A (3%ACN/0.1%TFA) to 50%B (97%ACN/0.1%TFA) in 70 minutes, followed by an increase up to 80%B in 5 minutes. The eluting peptides were on-line electrosprayed into the QStar XL Hybrid ESI Quadrupole time-of-flight tandem mass spectrometer, ESI-QTOF-MS/MS (Applied Biosystems, Framingham, MA; MDS Sciex, Concord, Ontario, Canada) provided with a nanospray source equipped with a New Objective ESI needle (10 μm tip diameter). Typical values for needle voltage were 2 kV in positive ion mode. The mass spectrometer was set to perform data acquisition in the positive ion mode, typically with a selected mass range of 300--1500 m/z. Peptides with +2 to +4 charge states were selected for tandem mass spectrometry, and the time of summation of MS/MS events was set to be 2 s. The three most abundant charged peptides above a 30 count threshold were selected for MS/MS and dynamically excluded for 60 s with 50 amu mass tolerance.

ProID software (Applied Biosystems) was used to identify proteins from the mass spectrometric datasets according to UniProt database (May 2005, 181,000 entries). Mass tolerance was set to 0.15 Da (MS) and 0.1 Da (MS/MS) and carboxamido-methylation and methionine oxidation were chosen as modifications for database search.

Results
=======

Sample stability
----------------

The stability of saliva at room temperature after sample collection from four male and three female volunteers was evaluated. Freshly collected saliva samples were either directly processed (time point 0) or left at room temperature for 4 hrs and processed as described in the sample pretreatment section. Aliquots taken at the two time points were then spotted in duplicate on CM10 weak cation exchange chips and protein profiles were obtained by SELDI-TOF-MS. Representative spectra obtained from the 1 to 10 kDa range are shown in [Figure 1](#f1-bmi-03-25){ref-type="fig"}. In this mass range degradation products of larger proteins can be expected. When comparing the protein profiles of fresh samples (0 hrs) of the seven volunteers (A--G) it is evident that there is already considerable variation, especially in the mass range of 1 to 5 kDa between the different individuals. This may be due to biological variation and/or may indicate different degrees of protein degradation between individuals. Also over the period of 4 hrs at room temperature many changes in the spectra can be observed ([Fig. 1](#f1-bmi-03-25){ref-type="fig"}). To find common peaks that were changed over the 4 hrs period in all seven samples we performed a cluster analyses on the acquired spectra. In total 11 differences were detected and listed in [Table 1](#t1-bmi-03-25){ref-type="table"} together with their fold change in peak intensity between the two conditions. Most peptides are decreased in abundance at 4 hrs, probably because they are further degraded into single amino acids during this period. However, 3 peptides with masses 2937 Da, 3370 Da and 4132 Da are increasing in time which indicates that they are relatively stable breakdown products of larger proteins. Although SELDI technology allows rapid comparison of sample composition, protein/peptide identification is troublesome because it involves purification of each degradation product. Therefore, we attempted to identify the 2937 Da breakdown product by direct SELDI-MS/MS which is possible for peptides with masses below 3000 Da. However, the 2937 Da peptide could not be fragmented by MS/MS even with the highest energy settings and argon as collision gas. This indicates that it is very stable, possibly due to a high degree of post-translational modifications such as glycosylation which may also explain its stability in vivo. As [Figure 2](#f2-bmi-03-25){ref-type="fig"} indicates, the three marker peptides can already be detected in "fresh" samples (0 hrs), although with lower intensities. This indicates that breakdown already starts during sample collection and suggests that these markers may be useful indicators of protein breakdown in saliva samples. We examined the protein degradation in saliva in detail to obtain more knowledge on the time frame of the degradation process and whether it was possible to inhibit degradation. Protein degradation could be caused by bacteria in the mouth cavity and/or by proteases present in saliva. Therefore, we studied the influence of sodium azide, an inhibitor of bacterial energy metabolism, and of a protease inhibitor cocktail consisting of PMSF, leupeptin (both serine and cysteine protease inhibitors) and EDTA, an inhibitor of metallo-proteases. Saliva samples were incubated for 0, 0.5, 1 and 4 hrs in the presence and absence of the above mentioned inhibitors. Subsequently, protein profiles were generated ([Fig. 3](#f3-bmi-03-25){ref-type="fig"}) and compared for differences by cluster analyses as described above. In [Figure 4](#f4-bmi-03-25){ref-type="fig"} the number of significant differences is depicted for the different conditions and the different time points compared to 0 hrs (control). For saliva without inhibitors already 19 differences were observed in the first 30 minutes incubation. Thereafter, the number of differences stabilizes. This can be explained by assuming that equilibrium has been reached at this point between the formation of peptides from the breakdown of larger proteins and the degradation of these peptides into single amino acids which are in the mass range of the matrix peaks and therefore are not detected. At 4 hrs 26 differences were observed compared to 0 hrs. This indicates that protein degradation in saliva is a relatively rapid process. It is also clear from [Figure 4](#f4-bmi-03-25){ref-type="fig"} that protein breakdown is almost not affected by the addition of azide to the samples, indicating that bacterial metabolism is not contributing much to the protein degradation process, at least for the first hour after collection. The protease inhibitor cocktail is more effective in slowing down the degradation process ([Fig. 4](#f4-bmi-03-25){ref-type="fig"}). At 4 hrs, 19 differences were observed in the presence of protease inhibitors compared to 26 differences in the control sample. Nevertheless, protein degradation is still substantial with the inhibitor cocktail used. Different inhibitors or combinations of inhibitors need to be evaluated to determine their effectiveness.

The saliva proteome
-------------------

To determine the saliva composition, saliva proteins were fractionated by SDS-PAGE ([Fig. 5](#f5-bmi-03-25){ref-type="fig"}). The whole lane was sliced into 30 bands and digested by trypsin. The digests of the bands were subjected to LC-MS/MS for protein identification, as described in detail in the Materials and Methods section. In total we identified 218 proteins, 182 with 99% confidence and 36 with 95% confidence. A complete list of identified proteins is shown in [Table 2](#t2-bmi-03-25){ref-type="table"}. Proteins were classified into 12 functional categories based on information from Swiss Prot, Source and Human Protein Reference Database. For each protein also the functional category is listed. In [Figure 6](#f6-bmi-03-25){ref-type="fig"} an overview of the different categories is given. The largest category (19.2%) consists of enzymes involved in metabolism, mainly in carbohydrate metabolism (12.8%). This includes enzymes such as α-amylase, lactate dehydrogenase, malate dehydrogenase and fructose-biphosphate aldolase. Another important category (17.9%) includes proteins that are involved in immune response and defense against bacteria. In this group there is a large cluster of IgG chains besides antibactericidal peptides such as dermcidin and bactericidal permeability-increasing protein. Also many proteins from bacterial origin were identified (11% of total). 10.6% of the proteins are involved in degradation. Six proteases were identified in this group e.g. kallikrein, cathepsin D and lysozyme C. Thirteen protease inhibitors are also part of this category such as cystatins, alpha-2-macroglobulin and TIMP-1. The proteases are likely to contribute to the rapid breakdown of saliva proteins that was described above. Also many structural proteins (14.7% of total) were found which are probably derived from cells lining the mouth cavity together with other intracellular proteins that were identified. The transport proteins (8.3% of total) are mainly serum-derived such as albumin, apolipoprotein A-1, transferrin, and ceruloplasmin. Minor categories of proteins are signaling (5.5%), protein modification (4.6%), cell growth and differentiation (2.3%), cell adhesion (3.7%), and proteins involved in maintaining redox status (2.3%). We also compared our results, listed in [Table 2](#t2-bmi-03-25){ref-type="table"}, to the HUPO plasma proteome initiative list of 3020 plasma proteins, identified with at least two peptides by LC-MS/MS ([www.bioinformatics.med.umich.edu/hupo/ppp](www.bioinformatics.med.umich.edu/hupo/ppp)). According to the HUPO list, 84 proteins (38.5%) identified in the current study and indicated in [Table 2](#t2-bmi-03-25){ref-type="table"} are also found in plasma. To determine the relevance of the identified proteins, we compared our results to seven other proteomics studies ([@b11-bmi-03-25]; [@b31-bmi-03-25]; [@b29-bmi-03-25]; [@b10-bmi-03-25]; [@b32-bmi-03-25]; [@b30-bmi-03-25]; [@b6-bmi-03-25]) on whole saliva composition. [Figure 7](#f7-bmi-03-25){ref-type="fig"} shows that there is only partial overlap with our study. Based on this analyses 83 new saliva proteins were identified in our study which are indicated in [Table 2](#t2-bmi-03-25){ref-type="table"}.

Discussion
==========

There is growing interest in using saliva as a diagnostic fluid because of its relatively simple and non-invasive collection procedures. A prerequisite for measuring diagnostic protein markers in saliva is that these proteins are stable in saliva. In this study we show that relatively rapid protein degradation occurs in whole saliva samples at room temperature. We developed a SELDI-based assay to quickly monitor sample integrity. With this assay we show that protein degradation in saliva at room temperature is rapid and starts already during sample collection and handling. Three degradation products with masses of 2937 Da, 3370 Da and 4132 Da were discovered that can be used to monitor the degradation process and to determine the quality of a saliva sample before protein analyses. These markers increase 2 to 7-fold over a period of 4 hrs storage at room temperature, suggesting they are stable breakdown products of larger proteins. The proteome analyses indicates that there are at least six proteases present in saliva (see [Table 2](#t2-bmi-03-25){ref-type="table"}) which are probably involved in the observed protein degradation. However, also 13 protease inhibitor proteins were identified which may counteract protease activity. Nevertheless, the overall balance is clearly in favour of degradation. Protein breakdown in saliva could be partly inhibited by a protease inhibitor cocktail targeting serine, cysteine and metallo-proteases. Also in another study, that investigated storage of saliva samples at different temperatures, only partially prevention of degradation was observed with a different inhibitor cocktail ([@b26-bmi-03-25]). More research is clearly needed to find more effective protease inhibitor cocktails to prevent degradation. A complicating factor in such studies will be that many protease inhibitors are peptides themselves or covalently bind to proteins thereby changing their masses. Both will interfere with proteomics measurements in biomarker discovery studies but may not interfere with ELISA-based measurements of individual proteins. Based on the results of our study we recommend to freeze samples immediately after collection, e.g. in liquid nitrogen, to minimize protein breakdown. Sample processing at 4 °C as well as the use of protease inhibitors can help to reduce degradation. Based on a study by Schipper et al. ([@b26-bmi-03-25]) long time storage at −80 °C is recommended.

Several different strategies have been employed to analyze the saliva proteome such as 2 D gel ([@b11-bmi-03-25]; [@b31-bmi-03-25]; [@b29-bmi-03-25]; [@b10-bmi-03-25]; [@b30-bmi-03-25]), capillary iso-electric focusing ([@b6-bmi-03-25]), and free flow electrophoresis ([@b32-bmi-03-25]). Our approach was to fractionate saliva proteins by SDS-PAGE followed by LC-MS/MS for protein identification. Overall 218 proteins were identified by this proteomics strategy, not applied to saliva before. From the identified proteins we deduced the main functions. These are: carbohydrate-breakdown, immune response/defence against bacteria, and protein degradation. By comparing our results with seven previous proteomics studies ([Fig. 7](#f7-bmi-03-25){ref-type="fig"}) on whole saliva composition we find only partial overlap with our study. 83 new saliva proteins from our study which were not previously identified are indicated in [Table 2](#t2-bmi-03-25){ref-type="table"}. These results show that with each proteomics strategy, partial overlapping subsets of saliva proteins are identified. Therefore, different proteomic approaches will contribute to a more comprehensive view of the saliva proteome. Many of the identified proteins are also found in plasma. Comparison with the HUPO plasma proteome database learned that 38.5% of the identified proteins can also be found in plasma. This relatively high percentage of plasma proteins in saliva illustrate the possibilities for use of saliva as an alternative to blood for diagnosis and biomarker discovery. However, protein breakdown in saliva samples poses a serious problem for quantitative measurements. We conclude that saliva can be a promising diagnostic fluid when precautions are taken towards protein breakdown.
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![Sample stability at room temperature. Protein profiles of saliva samples of seven volunteers (A--G) taken at 0 and 4 hrs of incubation at room temperature are shown for the mass range of 1000 to 10000 Da. Protein profiles were generated using CM10 proteinchips and 100 mM NH~4~Ac pH 4.0 as binding and washing buffer. CHCA was used as matrix.](BMI-03-25-g001){#f1-bmi-03-25}

![Detailed view of the SELDI profile of volunteer A (see also [Fig. 1](#f1-bmi-03-25){ref-type="fig"}) in the mass range of 2500 to 5000 Da for saliva samples taken at 0 and 4 hrs of incubation at room temperature. The labeled peaks are discovered degradation markers. The complete list of markers is shown in [Table 1](#t1-bmi-03-25){ref-type="table"}.](BMI-03-25-g002){#f2-bmi-03-25}

![Representative SELDI spectra of a saliva sample incubated at 0, 0.5, 1 and 4 hrs at room temperature in the absence (control) and presence of sodium azide, an inhibitor of bacterial metabolism, and a protease inhibitor cocktail.](BMI-03-25-g003){#f3-bmi-03-25}

![Number of significant differences in peak intensity between the different conditions (• control, + azide and ▴ protease inhibitors) and the different time points compared to 0 hrs. Differences were calculated from the spectra ([Fig. 3](#f3-bmi-03-25){ref-type="fig"}) for the mass ranges of 1000 to 20000 Da using cluster analyses of triplicate measurements of the samples. Clusters were defined using S/N \> 5 (first pass) and S/N \> 2 (second pass). Differences were considered significant if p \< 0.05.](BMI-03-25-g004){#f4-bmi-03-25}

![SDS-PAGE of saliva proteins. Lane 1 represents the molecular weight markers. Lane 2 represents proteins present in 10 μl of processed saliva. This lane was cut into 30 bands for further identification by LC-MS/MS.](BMI-03-25-g005){#f5-bmi-03-25}

![Functional categories of identified proteins, based on information from Swiss Prot, Source and Human Protein Reference Database.](BMI-03-25-g006){#f6-bmi-03-25}

![Venn diagrams comparing the proteome results obtained with this study (**A**) versus those achieved by Xie et al. ([@b32-bmi-03-25]) (**B**), Hu et al. ([@b10-bmi-03-25]) (**C**), Vitorino et al. ([@b29-bmi-03-25]) (**D**), Walz et al. ([@b30-bmi-03-25]) (**E**), Huang et al. ([@b11-bmi-03-25]) (**F**), Wilmarth et al. ([@b31-bmi-03-25]) (**G**), Guo et al. ([@b6-bmi-03-25]) (**H**). Only part of the data of the study by Guo et al. is publicly available and was used in this comparison.](BMI-03-25-g007){#f7-bmi-03-25}

###### 

Masses with significantly different peak intensities between 0 and 4 hrs of incubation of whole saliva at room temperature.

  Peak (m/z)   p-value   Fold change
  ------------ --------- -------------
  2937         0.0017    6.8
  3370         0.025     2.0
  4132         0.047     3.0
  4368         0.0017    −6.1
  4928         0.0017    −17.5
  5210         0.018     −3.7
  5376         0.0017    −16.5
  5839         0.018     −2.8
  7751         0.0017    −6.1
  10422        0.0088    −5.0
  15495        0.0017    −4.9

Clusters were determined using S/N \> 5 (first pass) and S/N \> 2 (second pass). Differences were considered significant if p \< 0.05.

###### 

List of proteins identified with 99% and 95% confidence in human saliva.

  Protein name                                                                                                                                Accession nr   Function                              Mass (Da)
  ------------------------------------------------------------------------------------------------------------------------------------------- -------------- ------------------------------------- -----------
  **99% confidence:**                                                                                                                                                                              
  14-3-3 protein beta/alpha                                                                                                                   P31946         Signalling                            27951
  14-3-3 protein zeta/delta[§](#tfn2-bmi-03-25){ref-type="table-fn"}                                                                          P63104         Signalling                            27745
  6-phosphogluconate dehydrogenase, decarboxylating                                                                                           P52209         Energy/metabolism                     53009
  78 kDa glucose-regulated protein precursor[§](#tfn2-bmi-03-25){ref-type="table-fn"}                                                         P11021         Protein Folding/Repair                72333
  Actin[§](#tfn2-bmi-03-25){ref-type="table-fn"}                                                                                              P60709         Structural/Cytoskeletal               41737
  Actin-like protein 3[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                                                                              P61158         Structural/Cytoskeletal               47240
  Actin-related protein 2/3 complex subunit 4[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                                                       P59998         Structural/Cytoskeletal               19536
  Adenine phosphoribosyltransferase                                                                                                           P07741         Energy/metabolism                     19477
  Adenosylhomocysteinase[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                                                                            P23526         Energy/metabolism                     47585
  Alcohol dehydrogenase \[NADP+\][\#](#tfn3-bmi-03-25){ref-type="table-fn"}                                                                   P14550         Energy/metabolism                     36442
  Alcohol dehydrogenase class IV mu/sigma chain[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                                                     P40394         Energy/metabolism                     40006
  Aldehyde dehydrogenase, dimeric NADP-preferring[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                                                   P30838         Energy/metabolism                     50379
  Aldo-keto reductase family1 member B10                                                                                                      O60218         Energy/metabolism                     36021
  Alpha enolase[§](#tfn2-bmi-03-25){ref-type="table-fn"}                                                                                      P06733         Energy/metabolism                     47038
  Alpha-1-acid glycoprotein 1 precursor[§](#tfn2-bmi-03-25){ref-type="table-fn"},[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                   P02763         Defense/Immunoresponse                23512
  Alpha-1-antitrypsin precursor[§](#tfn2-bmi-03-25){ref-type="table-fn"}                                                                      P01009         Protein Degradation/Inhibitor         46737
  Alpha-actinin 1[§](#tfn2-bmi-03-25){ref-type="table-fn"}                                                                                    P12814         Structural/Cytoskeletal               103058
  Apolipoprotein A-I precursor[§](#tfn2-bmi-03-25){ref-type="table-fn"}                                                                       P02647         Transport                             30778
  Arginase 1[§](#tfn2-bmi-03-25){ref-type="table-fn"}                                                                                         P05089         Energy/metabolism                     34735
  ATPase 4, plasma membrane-type[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                                                                    Q9SU58         Micro organism                        105718
  Bactericidal permeability-increasing protein precursor[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                                            P17213         Transport                             53396
  Calgranulin B[§](#tfn2-bmi-03-25){ref-type="table-fn"}                                                                                      P06702         Cell Adhesion/Communication           13242
  Carbonic anhydrase VI precursor[§](#tfn2-bmi-03-25){ref-type="table-fn"}                                                                    P23280         Energy/metabolism                     35365
  Carboxylesterase 2 precursor                                                                                                                O00748         Energy/metabolism                     61807
  Cathepsin D precursor                                                                                                                       P07339         Protein Degradation/Inhibitor         44552
  Ceruloplasmin precursor[§](#tfn2-bmi-03-25){ref-type="table-fn"}                                                                            P00450         Transport                             122205
  Chaperone protein dnaK[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                                                                            Q7NXI3         Micro organism                        69122
  Chitinase 3-like protein 2 precursor[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                                                              Q15782         Cell Growth/Differentiation           43501
  Chloride intracellular channel protein 1                                                                                                    O00299         Transport                             26792
  Clusterin precursor[§](#tfn2-bmi-03-25){ref-type="table-fn"}                                                                                P10909         Cell Growth/Differentiation           52495
  Cofilin, non-muscle isoform                                                                                                                 P23528         Structural/Cytoskeletal               18371
  Complement C3 precursor[§](#tfn2-bmi-03-25){ref-type="table-fn"}                                                                            P01024         Signalling                            187164
  Complement C4 precursor[§](#tfn2-bmi-03-25){ref-type="table-fn"}                                                                            P01028         Defense/Immunoresponse                192771
  Complement factor H precursor[§](#tfn2-bmi-03-25){ref-type="table-fn"},[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                           P08603         Energy/metabolism                     139070
  Coronin-1A                                                                                                                                  P31146         Structural/Cytoskeletal               50895
  Cystatin A[§](#tfn2-bmi-03-25){ref-type="table-fn"}                                                                                         P01040         Protein Degradation/Inhibitor         11006
  Cystatin B[§](#tfn2-bmi-03-25){ref-type="table-fn"}                                                                                         P04080         Protein Degradation/Inhibitor         11140
  Cystatin C precursor[§](#tfn2-bmi-03-25){ref-type="table-fn"}                                                                               P01034         Protein Degradation/Inhibitor         15799
  Cystatin D precursor                                                                                                                        P28325         Protein Degradation/Inhibitor         16080
  Cystatin S precursor                                                                                                                        P01036         Protein Degradation/Inhibitor         16214
  Cystatin SA precursor                                                                                                                       P09228         Protein Degradation/Inhibitor         16445
  Cystatin SN precursor                                                                                                                       P01037         Protein Degradation/Inhibitor         16362
  Dermcidin precursor[§](#tfn2-bmi-03-25){ref-type="table-fn"},[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                                     P81605         Defense/Immunoresponse                11284
  Desmocollin-2 precursor                                                                                                                     Q02487         Cell Adhesion/Communication           99962
  Desmoglein-3 precursor                                                                                                                      P32926         Cell Adhesion/Communication           107503
  Diablo homolog, mitochondrial precursor[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                                                           Q9NR28         Signalling                            27131
  Dihydroxy-acid dehydratase[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                                                                        Q8XWR1         Micro organism                        58965
  Dipeptidyl peptidase IV[§](#tfn2-bmi-03-25){ref-type="table-fn"},[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                                 P27487         Protein Degradation/Inhibitor         88279
  DNA polymerase IV[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                                                                                 Q9JYS8         Micro organism                        35966
  Elongation factor 1-alpha[§](#tfn2-bmi-03-25){ref-type="table-fn"}                                                                          P68104         Protein Synthesis                     50141
  Elongation factor 1-gamma                                                                                                                   P26641         Protein Synthesis                     49988
  Ezrin[§](#tfn2-bmi-03-25){ref-type="table-fn"},[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                                                   P15311         Cell Growth/Differentiation           69268
  F-actin capping protein beta subunit                                                                                                        P47756         Structural/Cytoskeletal               31219
  Farnesyl pyrophosphate synthetase[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                                                                 P14324         Energy/metabolism                     40532
  Fatty acid-binding protein, epidermal                                                                                                       Q01469         Energy/metabolism                     15033
  Fibrinogen gamma chain precursor[§](#tfn2-bmi-03-25){ref-type="table-fn"}                                                                   P02679         Protein Modification/Polymerization   51512
  FixC protein[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                                                                                      Q8Z9K9         Micro organism                        45687
  Fructose-bisphosphate aldolase A[§](#tfn2-bmi-03-25){ref-type="table-fn"}                                                                   P04075         Energy/metabolism                     39289
  Fructose-bisphosphate aldolase C                                                                                                            P09972         Energy/metabolism                     39325
  Galectin-3 binding protein precursor[§](#tfn2-bmi-03-25){ref-type="table-fn"}                                                               Q08380         Cell Adhesion/Communication           65331
  Galectin-7[§](#tfn2-bmi-03-25){ref-type="table-fn"}                                                                                         P47929         Cell Adhesion/Communication           14944
  Gelsolin precursor[§](#tfn2-bmi-03-25){ref-type="table-fn"}                                                                                 P06396         Structural/Cytoskeletal               85698
  Genome polyprotein[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                                                                                P17593         Micro organism                        255497
  Glucose-6-phosphate isomerase[§](#tfn2-bmi-03-25){ref-type="table-fn"}                                                                      P06744         Energy/metabolism                     63016
  Glutaminyl-tRNA synthetase[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                                                                        Q8EG26         Micro organism                        64103
  Glutathione S-transferase P                                                                                                                 P09211         Signalling                            23225
  Glyceraldehyde-3-phosphate dehydrogenase 1                                                                                                  P04406         Energy/metabolism                     35922
  Haptoglobin precursor                                                                                                                       P00738         Transport                             45205
  Heat shock 70 kDa protein 1[§](#tfn2-bmi-03-25){ref-type="table-fn"}                                                                        P08107         Protein Folding/Repair                70052
  Heat shock cognate 71 kDa protein[§](#tfn2-bmi-03-25){ref-type="table-fn"}                                                                  P11142         Protein Folding/Repair                70898
  Hemoglobin alpha chain                                                                                                                      P69905         Transport                             15126
  Hemoglobin beta chain                                                                                                                       Q9UK54         Transport                             13964
  Hemopexin precursor[§](#tfn2-bmi-03-25){ref-type="table-fn"}                                                                                P02790         Transport                             51676
  Hurpin                                                                                                                                      Q9UIV8         Protein Degradation/Inhibitor         44276
  Hypothetical 84.6 kDa protein[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                                                                     Q04263         Micro organism                        84602
  Ig alpha-1 chain C region                                                                                                                   P01876         Defense/Immunoresponse                37655
  Ig alpha-2 chain C region[§](#tfn2-bmi-03-25){ref-type="table-fn"}                                                                          P01877         Defense/Immunoresponse                36508
  Ig gamma-1 chain C region[§](#tfn2-bmi-03-25){ref-type="table-fn"}                                                                          P01857         Defense/Immunoresponse                36106
  Ig gamma-2 chain C region[§](#tfn2-bmi-03-25){ref-type="table-fn"}                                                                          P01859         Defense/Immunoresponse                35885
  Ig heavy chain V region MOPC 47A[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                                                                  P01786         Defense/Immunoresponse                12975
  Ig heavy chain V-II region NEWM[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                                                                   P01825         Defense/Immunoresponse                12790
  Ig heavy chain V-III region GAL[§](#tfn2-bmi-03-25){ref-type="table-fn"},[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                         P01781         Defense/Immunoresponse                12731
  Ig heavy chain V-III region HIL[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                                                                   P01771         Defense/Immunoresponse                13566
  Ig heavy chain V-III region TUR[§](#tfn2-bmi-03-25){ref-type="table-fn"},[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                         P01779         Defense/Immunoresponse                12431
  Ig heavy chain V-III region VH26 precursor[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                                                        P01764         Defense/Immunoresponse                12582
  Ig kappa chain C region[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                                                                           P01834         Defense/Immunoresponse                11609
  Ig kappa chain V-I region CAR[§](#tfn2-bmi-03-25){ref-type="table-fn"}                                                                      P01596         Defense/Immunoresponse                11608
  Ig kappa chain V-I region WEA[§](#tfn2-bmi-03-25){ref-type="table-fn"},[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                           P01610         Defense/Immunoresponse                11704
  Ig kappa chain V-I region                                                                                                                   P01611         Defense/Immunoresponse                11840
  Ig kappa chain V-III region B6[§](#tfn2-bmi-03-25){ref-type="table-fn"},[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                          P01619         Defense/Immunoresponse                11636
  Ig kappa chain V-III region GOL[§](#tfn2-bmi-03-25){ref-type="table-fn"}                                                                    P04206         Defense/Immunoresponse                11830
  Ig kappa chain V-IV region Len[§](#tfn2-bmi-03-25){ref-type="table-fn"}                                                                     P01625         Defense/Immunoresponse                12640
  Ig lambda chain C regions[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                                                                         P01842         Defense/Immunoresponse                11237
  Ig lambda chain V-I region NEW[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                                                                    P01701         Defense/Immunoresponse                11453
  Ig lambda chain V-I region WAH[§](#tfn2-bmi-03-25){ref-type="table-fn"},[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                          P04208         Defense/Immunoresponse                11725
  Ig lambda chain V-III region LOI[§](#tfn2-bmi-03-25){ref-type="table-fn"}                                                                   P80748         Defense/Immunoresponse                11935
  Ig lambda chain V-III region SH[§](#tfn2-bmi-03-25){ref-type="table-fn"}                                                                    P01714         Defense/Immunoresponse                11393
  Ig lambda chain V-IV region Hil                                                                                                             P01717         Defense/Immunoresponse                11517
  Ig mu chain C region                                                                                                                        P01871         Defense/Immunoresponse                49557
  Immunoglobulin J chain[§](#tfn2-bmi-03-25){ref-type="table-fn"}                                                                             P01591         Defense/Immunoresponse                15594
  Interleukin-1 receptor antagonist prec.                                                                                                     P18510         Defense/Immunoresponse                20055
  Kallikrein 1 precursor                                                                                                                      P06870         Protein Degradation/Inhibitor         28890
  Keratin, type I cuticular HA3-II[§](#tfn2-bmi-03-25){ref-type="table-fn"},[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                        Q14525         Structural/Cytoskeletal               46214
  Keratin, type I cytoskeletal 10                                                                                                             P13645         Structural/Cytoskeletal               59519
  Keratin, type I cytoskeletal 14[§](#tfn2-bmi-03-25){ref-type="table-fn"},[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                         P02533         Structural/Cytoskeletal               51490
  Keratin, type I cytoskeletal 16[§](#tfn2-bmi-03-25){ref-type="table-fn"}                                                                    P08779         Structural/Cytoskeletal               51137
  Keratin, type I cytoskeletal 9[§](#tfn2-bmi-03-25){ref-type="table-fn"}                                                                     P35527         Structural/Cytoskeletal               62129
  Keratin, type I microfibrillar 48 kDa[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                                                             P02534         Structural/Cytoskeletal               46674
  Keratin, type II cuticular HB4[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                                                                    Q9NSB2         Structural/Cytoskeletal               64895
  Keratin, type II cytoskeletal 1[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                                                                   P04104         Structural/Cytoskeletal               65092
  Keratin, type II cytoskeletal 1[§](#tfn2-bmi-03-25){ref-type="table-fn"}                                                                    P04264         Structural/Cytoskeletal               65886
  Keratin, type II cytoskeletal 2 epidermal[§](#tfn2-bmi-03-25){ref-type="table-fn"}                                                          P35908         Structural/Cytoskeletal               65865
  Keratin, type II cytoskeletal 4[§](#tfn2-bmi-03-25){ref-type="table-fn"}                                                                    P19013         Structural/Cytoskeletal               57285
  Keratin, type II cytoskeletal 5[§](#tfn2-bmi-03-25){ref-type="table-fn"}                                                                    P13647         Structural/Cytoskeletal               62447
  Keratin, type II cytoskeletal 6A                                                                                                            P02538         Structural/Cytoskeletal               59914
  Keratin, type II cytoskeletal 6D[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                                                                  P48667         Structural/Cytoskeletal               42468
  Keratin, type II cytoskeletal 6E                                                                                                            P48668         Structural/Cytoskeletal               59894
  Keratin, type II microfibrillar, component 7C[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                                                     P15241         Structural/Cytoskeletal               53682
  Lactoperoxidase precursor                                                                                                                   P22079         Redox                                 80288
  Lactotransferrin precursor[§](#tfn2-bmi-03-25){ref-type="table-fn"}                                                                         P02788         Transport                             78182
  Leukotriene A-4 hydrolase                                                                                                                   P09960         Energy/metabolism                     69154
  L-lactate dehydrogenase A chain[§](#tfn2-bmi-03-25){ref-type="table-fn"}                                                                    P00338         Energy/metabolism                     36558
  L-lactate dehydrogenase B chain[§](#tfn2-bmi-03-25){ref-type="table-fn"}                                                                    P07195         Energy/metabolism                     36507
  Long palate, lung and nasal epith. carc.ass. prot.1prec.                                                                                    Q8TDL5         Defense/Immunoresponse                52442
  L-plastin[§](#tfn2-bmi-03-25){ref-type="table-fn"}                                                                                          P13796         Structural/Cytoskeletal               70158
  Lysozyme C precursor                                                                                                                        P61626         Protein Degradation/Inhibitor         16537
  Macrophage capping protein                                                                                                                  P40121         Structural/Cytoskeletal               38518
  Malate dehydrogenase, cytoplasmic                                                                                                           P40925         Energy/metabolism                     36295
  Maspin precursor                                                                                                                            P36952         Protein Degradation/Inhibitor         42138
  Matrix metalloproteinase-9 precursor[§](#tfn2-bmi-03-25){ref-type="table-fn"}                                                               P14780         Protein Degradation/Inhibitor         78427
  Maturase K[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                                                                                        Q9GI85         Micro organism                        61017
  Metalloproteinase inhibitor 1 prec.[§](#tfn2-bmi-03-25){ref-type="table-fn"}                                                                P01033         Protein Degradation/Inhibitor         23171
  Moesin                                                                                                                                      P26038         Structural/Cytoskeletal               67689
  Monocyte differentiation antigen CD14 precursor[§](#tfn2-bmi-03-25){ref-type="table-fn"},[\#](#tfn3-bmi-03-25){ref-type="table-fn"}         P08571         Defense/Immunoresponse                40076
  Mucin 5B precursor                                                                                                                          Q9HC84         Cell Adhesion/Communication           590499
  Myeloperoxidase precursor                                                                                                                   P05164         Defense/Immunoresponse                83869
  Myoglobin[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                                                                                         P02144         Transport                             17053
  Myosin heavy chain, non-muscle type A[§](#tfn2-bmi-03-25){ref-type="table-fn"}                                                              P35579         Structural/Cytoskeletal               226401
  N-acetylglucosamine kinase[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                                                                        Q9UJ70         Energy/metabolism                     37244
  Neutrophil gelatinase-associated lipocalin prec.[§](#tfn2-bmi-03-25){ref-type="table-fn"}                                                   P80188         Transport                             22588
  Outer membrane usher protein pefC precursor[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                                                       P37868         Micro organism                        86370
  Peptidyl-prolyl cis-trans isomerase A                                                                                                       P62937         Protein Folding/Repair                17881
  Peroxiredoxin 5, mitochondrial precursor                                                                                                    P30044         Redox                                 22026
  Peroxiredoxin 6                                                                                                                             P30041         Redox                                 24904
  Phosphatidylethanolamine-binding protein                                                                                                    P30086         Protein Degradation/Inhibitor         20926
  Phosphoglucomutase[§](#tfn2-bmi-03-25){ref-type="table-fn"},[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                                      P36871         Energy/metabolism                     61318
  Phosphoglycerate kinase 1                                                                                                                   P00558         Energy/metabolism                     44483
  Phosphoglycerate mutase 1                                                                                                                   P18669         Energy/metabolism                     28673
  Phospholipid transfer protein prec.[§](#tfn2-bmi-03-25){ref-type="table-fn"},[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                     P55058         Energy/metabolism                     54739
  Plasminogen activator inhibitor-2 prec.[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                                                           P05120         Signalling                            46596
  Polymeric-immunoglobulin receptor precursor                                                                                                 P01833         Defense/Immunoresponse                83314
  Proactivator polypeptide precursor                                                                                                          P07602         Protein Degradation/Inhibitor         58113
  Profilin-1[§](#tfn2-bmi-03-25){ref-type="table-fn"}                                                                                         P07737         Structural/Cytoskeletal               14923
  Prolactin-inducible protein precursor[§](#tfn2-bmi-03-25){ref-type="table-fn"}                                                              P12273         Defense/Immunoresponse                16572
  Proline-rich protein 3 precursor peptide P-B)                                                                                               P02814         Unknown                               8188
  Prominin 1 precursor[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                                                                              O43490         Signalling                            97202
  Protein-glutamine glutamyltransferase E prec.[§](#tfn2-bmi-03-25){ref-type="table-fn"}                                                      Q08188         Energy/metabolism                     76632
  Purine nucleoside phosphorylase                                                                                                             P00491         Energy/metabolism                     32118
  Pyruvate kinase, isozymes M1/M2[§](#tfn2-bmi-03-25){ref-type="table-fn"}                                                                    P14618         Energy/metabolism                     57806
  Rab GDP dissociation inhibitor beta                                                                                                         P50395         Signalling                            50663
  Ras-related C3 botulinum toxin substrate 2[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                                                        P15153         Transport                             21429
  Rho GDP-dissociation inhibitor 2                                                                                                            P52566         Signalling                            22857
  S100 calcium-binding protein A7[§](#tfn2-bmi-03-25){ref-type="table-fn"}                                                                    P31151         Cell Growth/Differentiation           11326
  Salivary alpha-amylase precursor                                                                                                            P04745         Energy/metabolism                     57768
  Serine/threonine-protein kinase BRI1- like 2 precursor[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                                            Q9ZPS9         Energy/metabolism                     39280
  Serine/threonine-protein kinase RIPK4[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                                                             P57078         Energy/metabolism                     91611
  Serotransferrin precursor[§](#tfn2-bmi-03-25){ref-type="table-fn"}                                                                          P02787         Transport                             77050
  Short palate, lung and nasal epith.carc.ass.prot.2prec.                                                                                     Q96DR5         Transport                             27011
  Small proline-rich protein 3                                                                                                                Q9UBC9         Structural/Cytoskeletal               18154
  SPARC-like protein 1 precursor                                                                                                              Q14515         Protein Degradation/Inhibitor         75216
  Squamous cell carcinoma antigen 1[§](#tfn2-bmi-03-25){ref-type="table-fn"}                                                                  P29508         Protein Degradation/Inhibitor         44565
  Sugar fermentation stimulation protein homolog[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                                                    Q97VP5         Micro organism                        27830
  Thioredoxin[§](#tfn2-bmi-03-25){ref-type="table-fn"}                                                                                        P10599         Redox                                 11606
  Transaldolase                                                                                                                               P37837         Energy/metabolism                     37540
  Transcobalamin I precursor                                                                                                                  P20061         Transport                             48195
  Transgelin-2                                                                                                                                P37802         Structural/Cytoskeletal               22260
  Transketolase[§](#tfn2-bmi-03-25){ref-type="table-fn"}                                                                                      P29401         Energy/metabolism                     67878
  Triosephosphate isomerase isomerise[§](#tfn2-bmi-03-25){ref-type="table-fn"}                                                                P60174         Protein Folding/Repair                26538
  Tyrosine recombinase xerC                                                                                                                   Q8UC70         Micro organism                        34532
  Ubiquitin[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                                                                                         O46543         Protein Degradation/Inhibitor         8583
  Von Ebner's gland protein precursor                                                                                                         P31025         Transport                             19250
  Zinc-alpha-2-glycoprotein precursor[§](#tfn2-bmi-03-25){ref-type="table-fn"}                                                                P25311         Energy/metabolism                     33872
  **95% confidence proteins**                                                                                                                                                                      
  14-3-3 protein sigma[§](#tfn2-bmi-03-25){ref-type="table-fn"}                                                                               P31947         Signalling                            27774
  30S ribosomal protein S20[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                                                                         Q7VQL2         Micro organism                        10264
  50S ribosomal protein L5[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                                                                          Q8CRH2         Micro organism                        20236
  Acetyl-CoA acetyltransferase[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                                                                      P45359         Energy/metabolism                     41241
  Alanyl-tRNA synthetase[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                                                                            Q971J4         Micro organism                        103675
  Alpha-2-macroglobulin precursor[§](#tfn2-bmi-03-25){ref-type="table-fn"}                                                                    P01023         Protein Degradation/Inhibitor         163278
  Bact.l/permeability-increasing protein- like 1 prec.                                                                                        Q8N4F0         Transport                             49172
  Beta crystallin B1 (Beta-35)[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                                                                      P53674         Cell Growth/Differentiation           27892
  Carbonyl reductase \[NADPH\] 1[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                                                                    P16152         Energy/metabolism                     30244
  Carcinoembryonic antigen-related cell adh. mol.5prec.[§](#tfn2-bmi-03-25){ref-type="table-fn"},[\#](#tfn3-bmi-03-25){ref-type="table-fn"}   P06731         Defense/Immunoresponse                76796
  Catalase[§](#tfn2-bmi-03-25){ref-type="table-fn"}                                                                                           P04040         Redox                                 59625
  CD9 antigen (p24)[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                                                                                 P21926         Cell Adhesion/Communication           25285
  Chaperone protein htpG                                                                                                                      P61185         Micro organism                        73731
  Cystatin B[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                                                                                        Q862Z5         Protein Degradation/Inhibitor         11103
  Dihydrolipoyllysine-residue succinyltransferase[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                                                   P36957         Energy/metabolism                     48640
  Ethanolamine utilization protein[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                                                                  P41793         Micro organism                        49174
  F-actin capping protein alpha-2 subunit[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                                                           P47755         Structural/Cytoskeletal               32818
  Ferredoxin II[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                                                                                     P00237         Micro organism                        9962
  Genome polyprotein[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                                                                                P17594         Micro organism                        255428
  Glucose-6-phosphate 1-dehydrogenase[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                                                               P11413         Energy/metabolism                     59135
  Heat shock protein HSP 90-beta[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                                                                    P08238         Protein Folding/Repair                83133
  Hut operon positive regulatory protein[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                                                            P10943         Micro organism                        16064
  Hypothetical protein ynaA[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                                                                         P77658         Micro organism                        37060
  Hypothetical UPF0135 protein CPn0137[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                                                              Q9Z946         Micro organism                        27236
  Ig heavy chain V region UPC10[§](#tfn2-bmi-03-25){ref-type="table-fn"},[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                           P01811         Defense/Immunoresponse                13001
  Ig kappa chain V-II region TEW[§](#tfn2-bmi-03-25){ref-type="table-fn"}                                                                     P01617         Defense/Immunoresponse                12316
  Ig kappa chain V-III region NG9 precursor[§](#tfn2-bmi-03-25){ref-type="table-fn"},[\#](#tfn3-bmi-03-25){ref-type="table-fn"}               P01621         Defense/Immunoresponse                10729
  Myeloblastin precursor                                                                                                                      P24158         Protein Degradation/Inhibitor         27807
  Potential phospholipid-transporting ATPase VA[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                                                     O60312         Energy/metabolism                     167688
  Probable Na(+)/H(+) antiporter nhx-9                                                                                                        P35449         Micro organism                        75281
  Probable serine/threonine-protein kinase[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                                                          P28966         Micro organism                        65248
  Pyruvate kinase, isozymes R/L[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                                                                     P30613         Energy/metabolism                     61830
  Rho GDP-dissociation inhibitor 1                                                                                                            P52565         Signalling                            23076
  Serum albumin precursor[§](#tfn2-bmi-03-25){ref-type="table-fn"}                                                                            P02768         Transport                             69367
  Vinculin[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                                                                                          P18206         Cell adhesion/Communication           123668
  Zinc finger protein 446[\#](#tfn3-bmi-03-25){ref-type="table-fn"}                                                                           Q9NWS9         Signalling                            48957

Proteins that are also found in plasma according to the HUPO Plasma Proteome Initiative list of plasma proteins ([www.bioinformatics.med.umich.edu/app/hupo/ppp/](www.bioinformatics.med.umich.edu/app/hupo/ppp/)).

Novel saliva proteins identified in this study compared to seven previous studies (see [Fig. 7](#f7-bmi-03-25){ref-type="fig"}).
